Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis

Trial Profile

Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs GR MD 02 (Primary)
  • Indications Fibrosis; Non-alcoholic steatohepatitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms NASH-FX
  • Sponsors Galectin Therapeutics
  • Most Recent Events

    • 22 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 15 Nov 2016 Baseline patient characteristics and non-invasive assessment data, presented at The Liver Meeting 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 07 Oct 2016 According to a Galectin Therapeutics media release, data evaluating utility of non-invasive imaging methods in NASH-FX and NASH-CX trial to be presented at The Liver Meeting 2016 .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top